Unlocking the potential: integrating phytoconstituents and nanotechnology in skin cancer therapy – A comprehensive review DOI
Abhishek Tiwari, Abhishek Tiwari, Ajay Sharma

et al.

Journal of Complementary and Integrative Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 13, 2024

Skin carcinoma, which includes basal cell carcinoma (BCC), squamous (SCC), and melanoma, is influenced by various factors such as genetic predisposition, chemical exposures, immune system imbalances, ultraviolet (UV) radiation. This review delves into the mechanisms behind development of these cancers, exploring therapeutic potential microbial, plant derived compounds nanoparticles in advancing skin cancer treatments. Special attention given to cytotoxic effects anti-neoplastic agents from microbial sources on different lines, particularly melanoma. Additionally, highlights role phytochemicals - quercetin, resveratrol, curcumin alongside vitamins, terpenoids, sulforaphane, management cancers through like apoptosis induction cycle regulation. Recent advancements nanotechnology-based drug delivery systems, including NP microemulsion formulations, are also discussed for their enhanced ability specifically target cells. The diverse roles NPs therapy, especially terms targeted modulation, reviewed. These innovative formulations have showed improved penetration tumor-specific delivery, reduced systemic toxicity effectiveness.

Language: Английский

A translational framework to DELIVER nanomedicines to the clinic DOI
Paul Joyce, Christine Allen, Marı́a José Alonso

et al.

Nature Nanotechnology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 6, 2024

Language: Английский

Citations

38
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment DOI Creative Commons
Thuỳ Anh Bùi, Haoqi Mei, Rui Sang

et al.

EBioMedicine, Journal Year: 2024, Volume and Issue: 106, P. 105266 - 105266

Published: Aug. 1, 2024

The Chimeric Antigen Receptor (CAR) T cell therapy has emerged as a ground-breaking immunotherapeutic approach in cancer treatment. To overcome the complexity and high manufacturing cost associated with current ex vivo CAR products, alternative strategies to produce cells directly body have been developed recent years. These involve direct infusion of genes via engineered nanocarriers or viral vectors generate situ. This review offers comprehensive overview advancements development cell-targeted generation Additionally, it identifies challenges method potential these issues.

Language: Английский

Citations

20
Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy DOI Creative Commons
Jieun Han, Jaesung Lim, Chi‐Pin James Wang

et al.

Nano Convergence, Journal Year: 2023, Volume and Issue: 10(1)

Published: Aug. 7, 2023

Abstract Cancer immunotherapy, which harnesses the power of immune system, has shown immense promise in fight against malignancies. Messenger RNA (mRNA) stands as a versatile instrument this context, with its capacity to encode tumor-associated antigens (TAAs), cell receptors, cytokines, and antibodies. Nevertheless, inherent structural instability mRNA requires development effective delivery systems. Lipid nanoparticles (LNPs) have emerged significant candidates for cancer providing both protection enhanced intracellular efficiency. In review, we offer comprehensive summary recent advancements LNP-based systems, focus on strategies optimizing design mRNA-encoded therapeutics treatment. Furthermore, delve into challenges encountered field contemplate future perspectives, aiming improve safety efficacy immunotherapies. Graphical

Language: Английский

Citations

40
The next frontier in immunotherapy: potential and challenges of CAR-macrophages DOI Creative Commons
Jing Li,

Ping Chen,

Wenxue Ma

et al.

Experimental Hematology and Oncology, Journal Year: 2024, Volume and Issue: 13(1)

Published: Aug. 5, 2024

Abstract Chimeric antigen receptor macrophage (CAR-MΦ) represents a significant advancement in immunotherapy, especially for treating solid tumors where traditional CAR-T therapies face limitations. CAR-MΦ offers promising approach to target and eradicate tumor cells by utilizing macrophages’ phagocytic antigen-presenting abilities. However, challenges such as the complex microenvironment (TME), variability expression, immune suppression limit their efficacy. This review addresses these issues, exploring mechanisms of action, optimal construct designs, interactions within TME. It also delves into ex vivo manufacturing CAR-MΦ, discussing autologous allogeneic sources importance stringent quality control. The potential synergies integrating with existing cancer like checkpoint inhibitors conventional chemotherapeutics are examined highlight possible enhanced treatment outcomes. Furthermore, regulatory pathways scrutinized alongside established protocols cells, identifying unique considerations essential clinical trials market approval. Proposed safety monitoring frameworks aim manage adverse events, cytokine release syndrome, crucial patient safety. Consolidating current research insights, this seeks refine therapeutic applications, overcome barriers, suggest future directions transition from experimental platforms standard care options.

Language: Английский

Citations

12
The paths toward non-viral CAR-T cell manufacturing: A comprehensive review of state-of-the-art methods DOI

Yekta Metanat,

Patrik Viktor,

Ayesha Amajd

et al.

Life Sciences, Journal Year: 2024, Volume and Issue: 348, P. 122683 - 122683

Published: May 1, 2024

Language: Английский

Citations

11
In Situ Reprogramming of Immune Cells Using Synthetic Nanomaterials DOI

Shihong Nie,

Yuyang Qin,

Liyuan Ou

et al.

Advanced Materials, Journal Year: 2024, Volume and Issue: 36(15)

Published: Jan. 17, 2024

In the past decade, adoptive cell therapy with chimeric antigen receptor-T (CAR-T) cells has revolutionized cancer treatment. However, complexity and high costs involved in manufacturing current greatly inhibit its widespread availability access. To address this, situ therapy, which directly reprograms immune inside body, recently been developed as a promising alternative. Here, an overview of recent progress development synthetic nanomaterials is provided to deliver plasmid DNA or mRNA for reprogramming T macrophages, focusing especially on CAR therapies. Also, main challenges are discussed some approaches overcome these barriers fulfill clinical applications proposed.

Language: Английский

Citations

9
Steering the course of CAR T cell therapy with lipid nanoparticles DOI Creative Commons
Muhammad Babar Khawar, Ali Afzal,

Yue Si

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: June 28, 2024

Abstract Lipid nanoparticles (LNPs) have proven themselves as transformative actors in chimeric antigen receptor (CAR) T cell therapy, surpassing traditional methods and addressing challenges like immunogenicity, reduced toxicity, improved safety. Promising preclinical results signal a shift toward safer more effective CAR treatments. Ongoing research aims to validate these findings clinical trials, marking new era guided by LNPs utility therapy. Herein, we explore the preference for over methods, highlighting versatility of their delivery nucleic acids. Additionally, address key considerations, heralding Graphical

Language: Английский

Citations

8
Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy DOI
Colleen Foley, Sheridan L. Swan, Melody A. Swartz

et al.

The Journal of Immunology, Journal Year: 2024, Volume and Issue: 212(2), P. 188 - 198

Published: Jan. 2, 2024

The use of a patient's own immune or tumor cells, manipulated ex vivo, enables Ag- patient-specific immunotherapy. Despite some clinical successes, there remain significant barriers to efficacy, broad patient population applicability, and safety. Immunotherapies that target specific Ags, such as chimeric Ag receptor T cells dendritic cell vaccines, can mount robust responses against immunodominant but evolving heterogeneity antigenic downregulation drive resistance. In contrast, whole vaccines lysate-loaded the unique repertoire without prior neoantigen selection; however, efficacy be weak when lower-affinity clones dominate pool. Chimeric tumor-infiltrating lymphocyte therapies additionally face challenges related genetic modification, exhaustion, immunotoxicity. this review, we highlight engineering approaches opportunities these among four classes autologous therapies.

Language: Английский

Citations

7
Immunotherapy Study on Non-small-Cell Lung Cancer (NSCLC) Combined with Cytotoxic T Cells and miRNA34a DOI Creative Commons
Richa Pandey, Chien‐Chih Chiu, Li‐Fang Wang

et al.

Molecular Pharmaceutics, Journal Year: 2024, Volume and Issue: 21(3), P. 1364 - 1381

Published: Jan. 31, 2024

Immunotherapy has emerged as a promising approach for cancer treatment, and the use of microRNAs (miRNAs) therapeutic agents gained significant attention. In this study, we investigated effectiveness immunotherapy utilizing miRNA34a Jurkat T cells in inducing cell death non-small-cell lung cells, specifically A549 cells. Moreover, explored impact activation delivery using iron oxide nanorods (IONRs) on killing were cocultured with both activated inactivated before after miRNA34a. Surprisingly, our results revealed that even inactive capable This unexpected observation suggested presence alternative mechanisms by which can exert cytotoxic effects We stimulated anti-CD3/CD28 analyzed their efficacy compared to conjunction Our findings indicated significantly enhanced potential against counterparts. The combined treatment demonstrated highest level death, suggesting synergistic effect between miRNA therapy. Besides apoptosis mechanism cells' furthermore ferroptosis pathway, was found have an due IONRs agent inside

Language: Английский

Citations

6
M1-polarized macrophage-derived cellular nanovesicle-coated lipid nanoparticles for enhanced cancer treatment through hybridization of gene therapy and cancer immunotherapy DOI Creative Commons
Ha Eun Shin, Jun‐Hyeok Han, Seungyong Shin

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2024, Volume and Issue: 14(7), P. 3169 - 3183

Published: March 7, 2024

Optimum genetic delivery for modulating target genes to diseased tissue is a major obstacle profitable gene therapy. Lipid nanoparticles (LNPs), considered prospective vehicle nucleic acid delivery, have demonstrated efficacy in human use during the COVID-19 pandemic. This study introduces novel biomaterial-based platform, M1-polarized macrophage-derived cellular nanovesicle-coated LNPs (M1-C-LNPs), specifically engineered combined gene-immunotherapy approach against solid tumor. The dual-function system of M1-C-LNPs encapsulates Bcl2-targeting siRNA within and immune-modulating cytokines M1 nanovesicles (M1-NVs), effectively facilitating apoptosis cancer cells without impacting T NK cells, which activate intratumoral immune response promote granule-mediating killing tumor eradication. Enhanced retention was observed upon administration M1-C-LNPs, owing presence adhesion molecules on M1-NVs, thereby contributing superior growth inhibition. These findings represent promising strategy development targeted effective nanoparticle-based genetic-immunotherapy, with significant implications advancing biomaterial therapeutics.

Language: Английский

Citations

5